Skip to content
Research Article Open access CC BY 4.0

Effectiveness of Probiotics (Procite®) Supplementation on Uremic Toxins in Non-Dialysis Chronic Kidney Disease Patients: A Real-World Retrospective Analysis

Umapati Hegde, Yashpal Jadeja

International Journal of Advances in Nephrology Research · pp. 1–9 · Published 16 Jan 2025

10.9734/ijanr/2025/v8i167

Abstract

Background: Gut dysbiosis is linked to chronic kidney disease (CKD) and cardiovascular disease progression. By addressing dysbiosis, probiotics may enrich the gut microbiota, boost immunological response, restore intestinal permeability, and promote anti-inflammatory effects, possibly benefiting CKD patients. Probiotics have the potential to slow progression. A small number of studies have suggested that supplementation of probiotics may decrease CKD progression. Aim: To determine the effectiveness of Procite® (probiotics) supplementation in lowering uremic toxins in CKD patients. Study Design:  A real-world retrospective analysis. Methodology: A real-world retrospective analysis was conducted in a tertiary care hospital and included patients aged 18-75 years, with CKD stages 3-5, not on dialysis.  Patients (n=51) who had taken Procite® (which contains 70 billion colony-forming units (cfu) of probiotic strains) for at least 3 months were included in the analysis. Patient records were evaluated from baseline (day 0) and at 1 month and 3 months post-probiotic supplementation. Clinical and laboratory parameters, including serum creatinine and blood urea, were assessed to evaluate efficacy and safety outcomes. Results: A total of 51 CKD patients (M; F-39;12) with a mean age of 50.43 ± 14.7 years. Mean serum creatinine at baseline, 1 and 3 months after probiotic were 4.23 ± 2.14, 4.15 ± 1.96 and 4.06 ± 2.03, respectively. The reduction in serum creatinine was not statistically significant. At 3 months, 80.39% patients' serum creatinine was stable, 15.68% improved, and 3.92% worsened. The blood urea at baseline, 1 and 3 months were 45.66± 16.8, 41.17 ± 12.6 and 38.74 ± 12.7, respectively. Blood urea was significantly lower after 1 month (-4.49, P=0.003) and 3 months (-6.92, P<0.001). There were no specific adverse events. Conclusion: Supplementation of Procite® (Probiotics) in CKD leads to lowering blood urea, serum creatinine and stabilising the progression of the condition. Probiotics can be helpful to adjuvant therapy in the management of CKD.

Chronic kidney disease probiotic blood urea serum creatinine uremic toxins

References (23)

  1. 1 Fiber and Prebiotics: Mechanisms and Health Benefits [DOI]
  2. 2 Invited Review: The Scientific Basis of Lactobacillus acidophilus NCFM Functionality as a Probiotic [DOI]
  3. 3 Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY) [DOI]
  4. 4 A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future Perspectives [DOI]
  5. 5 Classification of Uremic Toxins and Their Role in Kidney Failure [DOI]
  6. 6 The probiotic L. casei Zhang slows the progression of acute and chronic kidney disease [DOI]
  7. 7 Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease [DOI]
  8. 8 Patient-centred approaches for the management of unpleasant symptoms in kidney disease [DOI]
  9. 9 Gut microbiome and kidney disease: a bidirectional relationship [DOI]
  10. 10 Randomized Controlled Trial of Strain-Specific Probiotic Formulation (Renadyl) in Dialysis Patients [DOI]
  11. 11 Probiotic strainLactobacillus plantarum299v increases iron absorption from an iron-supplemented fruit drink: a double-isotope cross-over single-blind study in women of reproductive age [DOI]
  12. 12 Impact of Probiotic Administration on Serum C-Reactive Protein Concentrations: Systematic Review and Meta-Analysis of Randomized Control Trials [DOI]
  13. 13 Gut Dysbiosis and the Intestinal Microbiome: Streptococcus thermophilus a Key Probiotic for Reducing Uremia [DOI]
  14. 14 Association between gut dysbiosis and chronic kidney disease: a narrative review of the literature [DOI]
  15. 15 The quest for a better understanding of chronic kidney disease complications: an update on uremic toxins [DOI]
  16. 16 Effect of Lactobacillus Rhamnosus on serum uremic toxins (phenol and P-Cresol) in hemodialysis patients: A double blind randomized clinical trial [DOI]
  17. 17 Microbiome, Immunosenescence, and Chronic Kidney Disease [DOI]
  18. 18 Use of probiotics in patients with chronic kidney disease on hemodialysis: a randomized clinical trial [DOI]
  19. 19 Enzobiotics—A Novel Therapy for the Elimination of Uremic Toxins in Patients with CKD (EETOX Study): A Multicenter Double-Blind Randomized Controlled Trial [DOI]
  20. 20 Benefit and Use of Prebiotics in Patients With Chronic Kidney Disease [DOI]
  21. 21 Dose Escalation, Safety and Impact of a Strain-Specific Probiotic (Renadyl™) on Stages III and IV Chronic Kidney Disease Patients [DOI]
  22. 22 A Prospective Randomised Case Control Study on the Role of Probiotics in Controlling Chronic Kidney Disease Progression [DOI]
  23. 23 MO563: Effect of Probiotics on Uremic Toxins Production and Inflammation in Patients Suffering from CKD Stage 3 and 4 [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

36

Page views

0

PDF downloads

11

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.